Close X
Saturday, September 21, 2024
ADVT 
International

More evidence suggests COVID-19 was in US by Christmas 2019

Darpan News Desk The Canadian Press, 15 Jun, 2021 10:22 AM
  • More evidence suggests COVID-19 was in US by Christmas 2019

A new analysis of blood samples from 24,000 Americans taken early last year is the latest and largest study to suggest that the new coronavirus popped up in the U.S. in December 2019 — weeks before cases were first recognized by health officials.

The analysis is not definitive, and some experts remain skeptical, but federal health officials are increasingly accepting a timeline in which small numbers of COVID-19 infections may have occurred in the U.S. before the world ever became aware of a dangerous new virus erupting in China.

“The studies are pretty consistent,” said Natalie Thornburg of the Centers for Disease Control and Prevention.

“There was probably very rare and sporadic cases here earlier than we were aware of. But it was not widespread and didn't become widespread until late February," said Thornburg, principal investigator of the CDC's respiratory virus immunology team.

Such results underscore the need for countries to work together and identify newly emerging viruses as quickly and collaboratively as possible, she added.

The pandemic coronavirus emerged in Wuhan, China in late 2019. Officially, the first U.S. infection to be identified was a traveler — a Washington state man who returned from Wuhan on Jan. 15 and sought help at a clinic on Jan. 19.

CDC officials initially said the spark that started the U.S. outbreak arrived during a three-week window from mid-January to early February. But research since then — including some done by the CDC — has suggested a small number of infections occurred earlier.

A CDC-led study published in December 2020 that analyzed 7,000 samples from American Red Cross blood donations suggested the virus infected some Americans as early as the middle of December 2019.

The latest study, published Tuesday online by the journal Clinical Infectious Diseases, is by a team including researchers at the National Institutes of Health. They analyzed blood samples from more than 24,000 people across the country, collected in the first three months of 2020 as part of a long-term study called “All Of Us” that seeks to track 1 million Americans over years to study health .

Like the CDC study, these researchers looked for antibodies in the blood that are taken as evidence of coronavirus infection, and can be detected as early as two weeks after a person is first infected.

The researchers say seven of the nine study participants — three from Illinois, and one each from Massachusetts, Mississippi, Pennsylvania, and Wisconsin — were infected earlier than any COVID-19 case was originally reported in those states.

One of the Illinois cases was infected as early as Christmas Eve, said Keri Althoff, an associate professor at the Johns Hopkins Bloomberg School of Public Health and the study's lead author.

It can be difficult to distinguish antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, from antibodies that fight other coronaviruses, including some that cause the common cold. Researchers in both the NIH and CDC studies used multiple types of tests to minimize false positive results, but some experts say it still is possible their 2019 positives were infections by other coronaviruses and not the pandemic strain.

“While it is entirely plausible that the virus was introduced into the United States much earlier than is usually appreciated, it does not mean that this is necessarily strong enough evidence to change how we're thinking about this," said William Hanage, a Harvard University expert on disease dynamics.

The NIH researchers have not followed up with study participants yet to see if any had traveled out of the U.S. prior to their infection. But they found it noteworthy that the seven did not live in or near New York City or Seattle, where the first wave of U.S. cases were concentrated.

“The question is how did, and where did, the virus take seed,” Althoff said. The new study indicates “it probably seeded in multiple places in our country,” she added.

 

MORE International ARTICLES

Extra safety scrutiny planned as virus vaccine worries grow

Extra safety scrutiny planned as virus vaccine worries grow
The poll from The Associated Press-NORC Center for Public Affairs Research found only 46% of Americans want a COVID-19 vaccine and another 29% are unsure.

Extra safety scrutiny planned as virus vaccine worries grow

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout
The COLA affects the personal finances of about 1 in 5 Americans, including Social Security recipients, disabled veterans and federal retirees, some 70 million people in all.

Retiree checks to rise 1.3% in 2021 amid coronavirus fallout

AP-NORC poll: New angst for caregivers in time of COVID-19

AP-NORC poll: New angst for caregivers in time of COVID-19
The Associated Press-NORC Center for Public Affairs Research poll finds that 17% of Americans say they are providing ongoing caregiving, part of an informal volunteer corps.

AP-NORC poll: New angst for caregivers in time of COVID-19

Am I immune to the coronavirus if I’ve already had it?

Am I immune to the coronavirus if I’ve already had it?
Reinfection so far has been rare. The best known example: Researchers in Hong Kong said a man had mild COVID-19 and then months later was infected again but showed no symptoms.

Am I immune to the coronavirus if I’ve already had it?

Antibody drugs are no cure but seem promising for COVID-19

Antibody drugs are no cure but seem promising for COVID-19
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines mimic an infection to spur antibody production.

Antibody drugs are no cure but seem promising for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19
Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19